What does Bivalirudin do?

Bivalirudin is an approved peptide anticoagulant used in procedural cardiac anticoagulation, especially PCI, and the source also notes acute coronary syndrome and heparin-induced thrombocytopenia contexts. It is a prescription hospital medication rather than a wellness or research-use peptide profile.

How does Bivalirudin work?

Bivalirudin directly inhibits thrombin. The source describes binding at both the catalytic site and exosite 1, which interferes with thrombin activity and fibrinogen interaction. It is also described as reversible and short acting, with thrombin able to cleave the molecule over time.

Is Bivalirudin FDA approved?

Yes. The source lists Bivalirudin as FDA approved and gives the clinical status as FDA Approved - PCI anticoagulation.

What side effects are reported for Bivalirudin?

The source reports bleeding, headache, thrombocytopenia, hypotension, acute stent thrombosis described as higher than heparin, and allergic reactions. Bleeding is listed with a 28% figure in the source.

What typical dose information is listed for Bivalirudin?

The source says community dosing data is limited. Its research dosing row lists 0.75 mg/kg IV bolus with IV bolus and infusion administration for the duration of the procedure.

Other FDA Approved - approved for specific uses

Bivalirudin

Also known as: Angiomax, Angiox

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

FDA-approved peptide anticoagulant used for PCI anticoagulation.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

0.75mg

IV bolus and infusion

Researched for

Cardiac procedures, anticoagulation

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

FDA-approved anticoagulant also known as Angiomax or Angiox.
Source describes IV use around PCI, with additional mention of acute coronary syndrome and heparin-induced thrombocytopenia settings.
Classified here as a single peptide based on the source's synthetic 20 amino acid peptide identity statement.
Community dosing information is limited; the source provides a label-linked research dosing row.
Research focus is cardiac procedures and anticoagulation.

How it's thought to work

Bivalirudin is described as a direct thrombin inhibitor derived from hirudin-related design. It binds thrombin at two functional regions, including the active catalytic site and exosite 1, and the source notes activity against clot-associated thrombin as well as circulating thrombin. Its anticoagulant effect is characterized as reversible and relatively short lived because thrombin can gradually cleave the molecule.

What the research shows

Where the research stands

The source describes a substantial clinical literature for Bivalirudin in PCI and acute coronary syndrome, including randomized comparisons with heparin-based strategies. Reported themes include similar ischemic protection in some comparisons, lower bleeding in several analyses, and discussion of net adverse clinical events when compared with heparin plus glycoprotein IIb/IIIa inhibition. The source also notes research on thrombin inhibition and collagen-dependent platelet activation during PCI. It flags ongoing nuance in the literature, including patient selection and early post-procedure stent thrombosis risk.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA Approved - PCI anticoagulation FDA Approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community data in the source is limited and points readers to research dosing rather than a standalone community regimen.

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

0.75 mg/kg IV bolus

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Duration of procedure
Administration: IV bolus and infusion

Timing & administration

Best time to take

As directed by procedural protocol

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The source ties timing to protocol and clinical context rather than a general daily schedule. Its broader timing note indicates that timing can vary by response and goals.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Bleeding
Headache
Thrombocytopenia
Hypotension
Acute stent thrombosis
Allergic reactions

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Bivalirudin

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Bivalirudin

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions